BiotechTube
Jupiter Endovascular

Jupiter Endovascular

Miami, United States· Est.
jupiterendo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Jupiter Endovascular is a private, clinical-stage medical device company pioneering a proprietary catheter stabilization technology called Transforming Fixation (TFX). Its lead program, the Vertex Pulmonary Embolectomy System, is currently in a pivotal trial (SPIRARE II) for treating pulmonary embolism, with promising early clinical data. The company is well-capitalized, having raised over $40 million in a Series B round led by Sonder Capital, and is led by a seasoned team of medtech executives with extensive experience in bringing cardiovascular devices to market.

CardiovascularPulmonary Embolism

Technology Platform

Transforming Fixation (TFX) - a technology that allows catheters to dynamically shift from flexible for navigation to firm for stable fixation at a treatment site.

Opportunities

The large, underserved patient population with acute pulmonary embolism represents a significant initial market.
The TFX platform technology has potential for broad expansion into other complex vascular and neurovascular interventions where catheter stability is a limiting factor, creating a pipeline-in-a-product opportunity.

Risk Factors

The company faces high clinical and regulatory risk as its entire value depends on the success of its single pivotal trial (SPIRARE II) and subsequent FDA approval.
As a pre-revenue startup, it also carries substantial commercialization risk, needing to build a sales force and secure reimbursement in a competitive market against established therapies.

Competitive Landscape

In pulmonary embolism, competition includes standard anticoagulant drugs, systemic thrombolytics, and adapted catheter thrombectomy devices (e.g., from Inari Medical, Penumbra). Jupiter's potential differentiation lies in its dedicated PE system with TFX for enhanced fixation. In the broader platform space, it may compete with large-cap medtech companies (e.g., Medtronic, Boston Scientific) with extensive R&D resources in catheter-based interventions.

More companies in Drug Delivery & Formulation →More companies in United States →